Home / Business and Economy / Indian Pharma Firm Torrent Gears Up for Semaglutide Generic Launches
Indian Pharma Firm Torrent Gears Up for Semaglutide Generic Launches
28 Jul
Summary
- Semaglutide patents expiring in 2026, opening door for generics
- Torrent Pharma planning launches of Ozempic and Wegovy generics in Brazil
- Torrent expects to be among the first to market with Wegovy generics
The patent on semaglutide, the popular GLP-1 compound sold under the brand names Wegovy and Ozempic, is set to expire in key markets like India and Brazil in March 2026. This has prompted Indian generic drugmakers, including Torrent Pharma, to prepare for the lucrative opportunity.
Torrent Pharma, based in Ahmedabad, has revealed plans to launch generic versions of both Ozempic and Wegovy in Brazil. The company's head of international business, Sanjay Gupta, told investors that Torrent is working to be among the first wave of semaglutide generic launches. This is particularly important for Wegovy, as the market has been shifting away from Ozempic since Wegovy's introduction in 2024.
Gupta noted that the current size of the Ozempic market in Brazil has declined significantly, and by the time the patent expires, it would be even smaller. In contrast, he expects Torrent to have a better chance of being an early entrant with Wegovy generics, as the market is expected to continue growing. The global GLP-1 market is projected to reach $100 billion by 2030, according to Goldman Sachs.
Torrent Pharma has reported strong financial results, with a 20% year-on-year increase in net profit and 11% revenue growth in the June quarter. The company's management is confident that its margins will remain stable through fiscal year 2026.
